Clinical Studies| Volume 20, ISSUE 1, P101-109, January 1998

Effects of doxazosin in patients with mild, intermediate, and severe benign prostatic hyperplasia

      This paper is only available as a PDF. To read, Please Download here.


      Traditionally, drug therapy for benign prostatic hyperplasia (BPH) has been reserved for patients with mild or moderate symptoms. The objective of this analysis was to compare responses to an alpha1-adrenergic receptor blocker, doxazosin, in patients with severe, intermediate, and mild disease. Data were analyzed from patients with symptomatic BPH who were enrolled in two 16-week, double-masked, placebo-controlled studies of doxazosin. In study 1, 163 hypertensive patients were stratified according to baseline maximum (Qmax) and mean (Qmean) urinary flow rate as having severe, intermediate, or mild disease. In study 2, 82 normotensive patients were stratified according to their baseline American Urological Association (AUA) BPH symptom severity score and modified Boyarsky symptom bothersomeness score. Overall, doxazosin was significantly more effective than placebo in improving Qmax and Qmean in study 1 and in improving the AUA-derived and modified Boyarsky scores in study 2. There were statistically significant differences in the response to treatment, as represented by Qmax, Qmean, and modified Boyarsky score, between patients with severe, intermediate, and mild disease. There were no significant differences in the AUA-derived scores of patients in the three severity groups. These results have important clinical implications, suggesting that the majority of BPH patients are candidates for a course of drug therapy, regardless of baseline disease status.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lu-Yao GL
        • Barry MJ
        • Chang CH
        • et al.
        • Prostate Patient Outcomes Research Team (PORT)
        Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes.
        Urology. 1994; 44: 692-698
        • Gee WF
        • Holtgrewe HL
        • Albertsen PC
        • et al.
        Practice trends in the diagnosis and management of benign prostatic hyperplasia in the United States.
        J Urol. 1995; 154: 205-206
        • McConnell JD
        • Barry MJ
        • Bruskewitz RC
        • et al.
        Benign Prostatic Hyperplasia: Diagnosis and Treatment. Quick Reference Guide for Clinicians. Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services, Rockville, MD1994 (AHCPR Publication No. 94-0583)
        • Cockett AT
        • Aso Y
        • Denis L
        • et al.
        Recommendations of the International Consensus Committee.
        in: Cockett ATK Khoury S Aso Y Proceedings of the 3rd International Consultation on Benign Prostatic Hyperplasia (BPH). Scientific Communication International Ltd, Jersey, UK1996: 625-640
        • Kaplan SA
        • Goluboff ET
        • Olsson CA
        • et al.
        Effect of demographic factors, urine peak flow rates, and Boyarsky symptom scores on patient treatment choice in benign prostatic hyperplasia.
        Urology. 1995; 45: 398-405
      1. Men's Experience and Knowledge Concerning Enlarged Prostate. The Gallup Organization, Princeton, NJ1989 (Report No. G089206)
        • Gillenwater JY
        • Conn RL
        • Chrysant SG
        • et al.
        • Multicenter Study Group
        Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: A double-blind, placebo-controlled, dose-response multicenter study.
        J Urol. 1995; 154: 110-115
        • Fawzy A
        • Braun K
        • Lewis GP
        • et al.
        • Multicenter Study Group
        Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study.
        J Urol. 1995; 154: 105-109
        • Barry MJ
        • Girman CJ
        • O'Leary MP
        • et al.
        Using repeated measures of symptom score, uroflowmetry and PSA in the clinical management of prostatic disease.
        J Urol. 1995; 153: 99-103
        • Barry MJ
        • Fowler Jr, FJ
        • O'Leary MP
        • et al.
        The American Urological Association symptom index for benign prostatic hyperplasia.
        J Urol. 1992; 148: 1549-1557
        • Boyarsky S
        • Jones G
        • Paulson DF
        • Prout Jr, GR
        A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy.
        Trans Am Assoc Genito-Urin Surg. 1977; 68: 29-32
        • Bosch JLHR
        • Hop WCJ
        • Kirkels WJ
        • Schröder FH
        The International Prostate Symptom Score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume.
        Br J Urol. 1995; 75: 622-630
        • Barry MJ
        • Cockett ATK
        • Holtgrewe HL
        • et al.
        Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia.
        J Urol. 1993; 150: 351-358
        • Roehrborn CG
        • Siegel RL
        Safety and efficacy of doxazosin in benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies.
        Urology. 1996; 48: 406-415
        • Boyle P
        • Gould AL
        Prostate volume predicts outcome of treatment of BPH with finasteride: Meta-analysis of randomized clinical trials.
        J Urol. 1996; 155 (Abstract 1044): 572A
        • Bruskewitz RC
        • Wasson J
        • Reda DJ
        • Barrett L
        Tests which predict outcome following transurethral resection of the prostate.
        J Urol. 1996; 155 (Abstract 1049): 573A